Julie Chang, MD

Trials

Studies that name Julie Chang, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:39 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT03311126 · Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

  University of Wisconsin, Madison · terminated · Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma · principal investigator
• Ph2
  NCT01754870 · Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

  University of Wisconsin, Madison · withdrawn · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) · principal investigator
• Ph2
  NCT01754857 · Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL

  University of Wisconsin, Madison · completed · Lymphoid Leukemia, Small Lymphocytic Lymphoma, Lymphoma, Non-Hodgkin · principal investigator
• Ph2
  NCT00974233 · Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

  University of Wisconsin, Madison · completed · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 06:39 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.